Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections.
Kauf TL, Prabhu VS, Medic G, Borse RH, Miller B, Gaultney J, Sen SS, Basu A. Kauf TL, et al. Among authors: prabhu vs. BMC Infect Dis. 2017 Apr 28;17(1):314. doi: 10.1186/s12879-017-2408-7. BMC Infect Dis. 2017. PMID: 28454524 Free PMC article.
Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010).
Shrestha SS, Swerdlow DL, Borse RH, Prabhu VS, Finelli L, Atkins CY, Owusu-Edusei K, Bell B, Mead PS, Biggerstaff M, Brammer L, Davidson H, Jernigan D, Jhung MA, Kamimoto LA, Merlin TL, Nowell M, Redd SC, Reed C, Schuchat A, Meltzer MI. Shrestha SS, et al. Among authors: prabhu vs. Clin Infect Dis. 2011 Jan 1;52 Suppl 1:S75-82. doi: 10.1093/cid/ciq012. Clin Infect Dis. 2011. PMID: 21342903
Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States.
Prabhu VS, Solomkin JS, Medic G, Foo J, Borse RH, Kauf T, Miller B, Sen SS, Basu A. Prabhu VS, et al. Antimicrob Resist Infect Control. 2017 Oct 27;6:107. doi: 10.1186/s13756-017-0264-2. eCollection 2017. Antimicrob Resist Infect Control. 2017. PMID: 29090091 Free PMC article.
Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials.
Basu A, Prabhu VS, Dorr MB, Golan Y, Dubberke ER, Cornely OA, Heimann SM, Pedley A, Xu R, Hanson ME, Marcella S. Basu A, et al. Among authors: prabhu vs. Open Forum Infect Dis. 2018 Nov 15;5(11):ofy218. doi: 10.1093/ofid/ofy218. eCollection 2018 Nov. Open Forum Infect Dis. 2018. PMID: 30460321 Free PMC article.
43 results